Developing machine‐learning‐based amyloidogenicity predictors with Cross‐Beta DB

IF 13 1区 医学 Q1 CLINICAL NEUROLOGY Alzheimer's & Dementia Pub Date : 2025-01-08 DOI:10.1002/alz.14510
Valentin Gonay, Michael P. Dunne, Javier Caceres‐Delpiano, Andrey V. Kajava
{"title":"Developing machine‐learning‐based amyloidogenicity predictors with Cross‐Beta DB","authors":"Valentin Gonay, Michael P. Dunne, Javier Caceres‐Delpiano, Andrey V. Kajava","doi":"10.1002/alz.14510","DOIUrl":null,"url":null,"abstract":"INTRODUCTIONThe importance of protein amyloidogenesis, associated with various diseases and functional roles, has driven the creation of computational predictors of amyloidogenicity. The accuracy of these predictors, particularly those utilizing artificial intelligence technologies, heavily depends on the quality of the data.METHODSWe built Cross‐Beta DB, a database containing high‐quality data on known cross‐β amyloids formed under natural conditions. We used it to train and benchmark several machine‐learning (ML) algorithms to predict amyloid‐forming potential of proteins.RESULTSWe developed the Cross‐Beta predictor using an Extra trees ML algorithm, which outperforms other amyloid predictors with the highest F1 score (0.852) and accuracy (0.844) compared to existing methods.DISCUSSIONThe development of the Cross‐Beta DB database and a new ML‐based Cross‐Beta predictor may enable the creation of personalized risk profiles for neurodegenerative diseases and other amyloidoses—especially as genome sequencing becomes more affordable.Highlights<jats:list list-type=\"bullet\"> <jats:list-item>Accuracy of ML‐based predictors depends on the quality of training data</jats:list-item> <jats:list-item>We built Cross‐Beta DB, a database of high‐quality data on naturally‐occurring amyloids</jats:list-item> <jats:list-item>Using this data, we developed an amyloid predictor that outperforms other predictors</jats:list-item> <jats:list-item>This computational tool enables the creation of risk profiles for neurodegenerative diseases</jats:list-item> </jats:list>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"35 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/alz.14510","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

INTRODUCTIONThe importance of protein amyloidogenesis, associated with various diseases and functional roles, has driven the creation of computational predictors of amyloidogenicity. The accuracy of these predictors, particularly those utilizing artificial intelligence technologies, heavily depends on the quality of the data.METHODSWe built Cross‐Beta DB, a database containing high‐quality data on known cross‐β amyloids formed under natural conditions. We used it to train and benchmark several machine‐learning (ML) algorithms to predict amyloid‐forming potential of proteins.RESULTSWe developed the Cross‐Beta predictor using an Extra trees ML algorithm, which outperforms other amyloid predictors with the highest F1 score (0.852) and accuracy (0.844) compared to existing methods.DISCUSSIONThe development of the Cross‐Beta DB database and a new ML‐based Cross‐Beta predictor may enable the creation of personalized risk profiles for neurodegenerative diseases and other amyloidoses—especially as genome sequencing becomes more affordable.Highlights Accuracy of ML‐based predictors depends on the quality of training data We built Cross‐Beta DB, a database of high‐quality data on naturally‐occurring amyloids Using this data, we developed an amyloid predictor that outperforms other predictors This computational tool enables the creation of risk profiles for neurodegenerative diseases
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Alzheimer's & Dementia
Alzheimer's & Dementia 医学-临床神经学
CiteScore
14.50
自引率
5.00%
发文量
299
审稿时长
3 months
期刊介绍: Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
期刊最新文献
Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup The Taiwan‐ADNI workflow toward integrating plasma p‐tau217 into prediction models for the risk of Alzheimer's disease and tau burden Developing machine‐learning‐based amyloidogenicity predictors with Cross‐Beta DB The etiology and prevention of early-stage tau pathology in higher cortical circuits: Insights from aging rhesus macaques
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1